NCT05922904View on ClinicalTrials.gov

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Brentuximab vedotin

Given by IV (vein)

DRUG

Doxorubicin Hydrochloride

Given by IV (vein)

DRUG

Pembrolizumab

Given by IV (vein)

DRUG

Dacarbazine

Given by IV (vein)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05922904 - PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter